Fact-Finding in Eligibility Analysis: Reviewed De Novo? from patentlyo.com Prism Tech v. T-Mobile USA (Supreme Court 2017) [Prism Technologies Petition] The district court sided with the patentee – Prism Tech’s – finding the user-authentication claims eligible under section 101. Important for the petition here, the ...
Share via E–mail | Twitter | Facebook
Book Review: The New Intellectual Property of Health from ipkitten.blogspot.com If reading is good for your health, then surely reading about the IP of health is even better. Enter Alberto Alemanno and Enrico Bonadio's edited volume, "The New Intellectual Property of Health: Beyond Plain ...
Share via E–mail | Twitter | Facebook
Bayer Pharma AG v. Watson Laboratories, Inc. (Fed. Cir. 2017) from www.patentdocs.org By Kevin E. Noonan -- The Federal Circuit reversed a finding of non-obviousness on Friday based on clear error by the District Court on factual underpinnings of its obviousness determination, in Bayer Pharma AG v. Watson ...
Share via E–mail | Twitter | Facebook
Challenging Alice at the Supreme Court? from patentlyo.com Recognicorp v. Nintendo (Supreme Court 2017) [RecogPetition] The new Supreme Court petition for writ of certiorari asks the following questions: In Alice Corp. Pty. Ltd. v. CLS Bank Int’l, 134 S. Ct. 2347 (2014 ...
Share via E–mail | Twitter | Facebook
WIPO Vaccines Report Contestable, Advocate Says, With UN High-Level Panel Misquoted from www.ip-watch.org The World Intellectual Property Organization this week held an event that delved into research, markets and access for vaccines with panels that showed unusual breadth of representation for the UN IP agency. But health advocates ...
Share via E–mail | Twitter | Facebook
First Consultations Held On WHO Pandemic Flu Framework Options from www.ip-watch.org The World Health Organization is consulting member states and stakeholders on the future of its mechanism to help prepare the world for the next influenza pandemic. It is particularly asking whether countries should submit not ...
Share via E–mail | Twitter | Facebook